Two Ebola drugs show promise amid ongoing outbreak.

@article{Maxmen2019TwoED,
  title={Two Ebola drugs show promise amid ongoing outbreak.},
  author={Amy Maxmen},
  journal={Nature},
  year={2019}
}
  • A. Maxmen
  • Published 12 August 2019
  • Medicine
  • Nature
People who receive either therapy soon after infection have a 90% survival rate, according to data from a clinical trial in the Democratic Republic of the Congo. People who receive either therapy soon after infection have a 90% survival rate, according to data from a clinical trial in the Democratic Republic of the Congo. 

Ebola Virus Disease and Current Therapeutic Strategies: A Review.

The epidemiology of Ebola virus and the current situation in terms of prevention, diagnosis, and treatment of the disease are reviewed.

Generation and Characterization of a Mouse-Adapted Makona Variant of Ebola Virus

A novel mouse-adapted (MA)-EBOV based on the 2014 Makona isolate is generated by inserting EBOV/Mayinga-MA mutations into the E BOV/Makona genome, followed by serial passaging of the rescued virus in suckling mice.

Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection

A systematic review of mathematical models of the Ebola virus disease

ABSTRACT Several studies have surveyed the literature of mathematical modelling of the Ebola virus disease (EVD). However, most of these reviews did not report any work published after January 2016.

Nonstandard finite difference method revisited and application to the Ebola virus disease transmission dynamics

We provide effective and practical guidelines on the choice of the complex denominator function of the discrete derivative as well as on the choice of the nonlocal approximation of nonlinear terms in

Clonal Wars: Monoclonal Antibodies Against Infectious Pathogens

The role of monoclonal antibodies is discussed and the effort to identify potent human monoclotal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is described, including the study on bispecific antibodies that neutralize SARS- CoV- 2 variants of concern.